Business
Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance
Q2'25 Total Net Revenue of $302m; Q2'25 SUBLOCADE® Net Revenue of $209m, up 9% Year-over-YearIndivior Action Agenda Underway to Strengthen Business and
About this update from Indivior Pharmaceuticals, Inc.
[{"type":"text","content":"Q2'25 Total Net Revenue of $302m; Q2'25 SUBLOCADE® Net Revenue of $209m, up 9% Year-over-YearIndivior Action Agenda Underway to Strengthen Business and Generate Operational Momentum Conference Call Scheduled for Today at 8:00 A.M. EDTRICHMOND, Va., July 31, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today reported its financial results for the second quarter ended June 30, 2025, and provided a business update.\n\n \n \n \n \n \n \n\n \n\"SUBLOCADE® net revenue and pricing stability in SUBOXONE® Film in the U.S. drove solid results in the second quarter, leading us to raise our 2025 financial guidance,\" said Joe Ciaffoni, Chief Executive Officer. \"In the second half of 2025, we are focused on implementing Phase 1 of the Indivior Action Agenda, Generate Momentum, which includes growing U.S. SUBLOCADE net revenue and simplifying the organization to generate operational momentum. We are committed to achieving our financial guidance for the year, investing in U.S. SUBLOCADE growth and implementing organizational changes that will strongly position us to advance to Phase 2 of the Indivior Action Agenda, Accelerate, at the start of 2026 and immediately realize bottom line accretion.\"\n\"We are increasing our 2025 financial guidance to reflect better-than-expected net revenue performance in the first half of the year,\" said Ryan Preblick, Chief Financial Officer. \"Our expectations for total net revenue and adjusted EBITDA are increasing by $65 million and $48 million, respectively, at the mid-points from our original guidance.\"\nBusiness Highlights\nGrew total SUBLOCADE Q2'25 net revenue to $209m, up 9% year-over-year and 19% versus Q1'25. Q2'25 U.S. SUBLOCADE net revenue increased 9% to $195m versus Q2'24 and 20% versus Q1'25. Growth was primarily volume driven.Initiated the Indivior Action Agenda with workstreams focused on U.S. SUBLOCADE growth and reducing organizational complexity. These efforts are expected to support long-term growth with significant operating leverage and durable cash generation.Strengthened Executive Team and Board of Directors with the addition of Patrick Barry, Chief Commercial Officer, Vanessa Procter, Executive Vice President of Corporate Affairs and Tony Kingsley, Independent Director.Completed London Stock Exchange (LSE) cancellation effective July 24, 2025. INDV now trades exclusively on Nasd...